Ayala Pharmaceuticals is a clinical stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Co.'s portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway using gamma secretase inhibitors. Gamma secretase is the enzyme responsible for Notch activation and, when inhibited, turns off the Notch pathway activation. Aberrant activation of the Notch pathway has long been implicated in various solid tumor and hematological cancers and has often been associated with more aggressive cancers. We show 35 historical shares outstanding datapoints in our ADXS shares outstanding history coverage, used to compute ADXS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADXS market cap history over the course of time is important for investors
interested in comparing ADXS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADXS versus a peer is one thing; comparing
ADXS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADXS can fluctuate over the course of history.
With this page we aim to empower investors researching ADXS by allowing them to research the ADXS market cap history. |
Free ADXS Email Alerts:
Video: The Importance of Market Cap
